Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes

Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793–1801

Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, Mohan V (2006) Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance—the Chennai Urban Rural Epidemiology Study (CURES). Metabolism 55:1232–1238

Gokulakrishnan K, Deepa R, Mohan V (2008) Association of high sensitivity C-reactive protein [hsCRP] and tumour necrosis factor-alpha [TNF-alpha] with carotid intimal medial thickness in subjects with different grades of glucose intolerance—the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem 41:480–485

Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA (2007) Visfatin, TNFα and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 39:758–763

Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M (2009) Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and Type 2 diabetes patients. Mol Cell Biochem 324:173–181

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

Lynn FC (2009) Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 20:452–459

Lindsay MA (2008) microRNAs and the immune response. Trends Immunol 29:343–351

Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481–12486

Hou J, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X (2009) MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183:2150–2158

Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK (2008) Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther 10:R101

Alberti KG, Zimmet PZ (1998) Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO Consultation. Diabet Med 15:539–553

Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, Mohan V (2003) The Chennai Urban Rural Epidemiology Study (CURES)—study design and methodology (urban component) (CURES-I). J Assoc Physicians India 51:863–870

Balasubramanyam M, Kimura M, Aviv A, Gardner JP (1993) Kinetics of calcium transport across the lymphocyte plasma membrane. Am J Physiol 265:C321–C327

Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248

Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA (2008) Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 31:2338–2343

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999–3004

Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 58:1284–1292

Sonkoly E, Stahle M, Pivarcsi A (2008) MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 33:312–315

Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60:1065–1075

Lin SL, Chiang A, Chang D, Ying SY (2008) Loss of miR-146a function in hormone-refractory prostate cancer. RNA 14:417–424

Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M (2001) Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract 52:119–123

Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA (1996) The expression of TNF Alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111–1116

Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK (2005) Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939–2945

Pedersen M, Bruunsgaard H, Weis N, Hendel HW, Andreassen BU, Eldrup E, Dela F, Pedersen BK (2003) Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124:495–502

Huang Y, Li T, Sane DC, Li L (2004) IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem 279:51697–51703

Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM (2007) The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp Mol Pathol 82:280–283

Liu S, Lutz J, Chang J, Liu D, Heemann U, Baumann M (2010) TRAF6 knockdown promotes survival and inhibits inflammatory response to lipopolysaccharides in rat primary renal proximal tubule cells. Acta Physiol (Oxf) 199:339–346

Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity- and diet induced insulin resistance with salicylates or targeted disruption of IkkB. Science 293:1673–1677

Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKKB and NF-kB. Nat Med 11:183–190

Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A, Nawroth PP (1998) Insufficient glycemic control increases nuclear factor k B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21:1310–1316

Adaikalakoteswari A, Rema M, Mohan V, Balasubramanyam M (2007) Oxidative DNA damage and augmentation of poly(ADP-ribose) polymerase/nuclear factor-kappa B signaling in patients with type 2 diabetes and microangiopathy. Int J Biochem Cell Biol 39:1673–1684

Patel S, Santani D (2009) Role of NF-kappaB in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 61:595–603

Lin R, Génin P, Mamane Y, Hiscott J (2000) Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol 20:6342–6353

Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446

Rønn SG, Börjesson A, Bruun C, Heding PE, Frobøse H, Mandrup-Poulsen T, Karlsen AE, Rasschaert J, Sandler S, Billestrup N (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51:1873–1882

Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O, Fernandez-Vizarra P, Mallavia B, Flores C, Sanz A, Blanco J, Mezzano S, Ortiz A, Egido J, Gomez-Guerrero C (2010) Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 21:763–772

Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N (2004) Suppressor of cytokine signalling (SOCS)-3 protects β cells against IL-1β-mediated toxicity through inhibition of multiple nuclear factor-kB-regulated proapoptotic pathways. Diabetologia 47:1998–2011

Frobøse H, Rønn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, Billestrup N (2006) Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol 20:1587–1596

Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, Sommer SS, Rossi JJ (2009) SNPs in human miRNA genes affect biogenesis and function. RNA 15:1640–1651

Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105:7269–7274

Granjon A, Gustin MP, Rieusset J, Lefai E, Meugnier E, Güller I, Cerutti C, Paultre C, Disse E, Rabasa-Lhoret R, Laville M, Vidal H, Rome S (2009) The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes 58:2555–2564

Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM (2009) Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 302:1186–1194